Spruce Biosciences, Inc.
SPRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $5 | $0 | $11 | $21 |
| G&A Expenses | $3 | $3 | $4 | $3 |
| SG&A Expenses | $3 | $3 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $8 | $3 | $14 | $25 |
| Operating Income | -$8 | -$3 | -$14 | -$24 |
| % Margin | – | – | – | -3,453.9% |
| Other Income/Exp. Net | $0 | $1 | $0 | $1 |
| Pre-Tax Income | -$8 | -$2 | -$14 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$2 | -$14 | -$24 |
| % Margin | – | – | – | -3,380.1% |
| EPS | -14.58 | -3.41 | -24 | -43.5 |
| % Growth | -327.6% | 85.8% | 44.8% | – |
| EPS Diluted | -14.58 | -3.41 | -24 | -43.5 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$2 | -$14 | -$23 |
| % Margin | – | – | – | -3,370.7% |